Berlin \u2014 SMP provi\u00added legal advice to 1717 Life Science Ventures on the sale of its stake in drug deve\u00adlo\u00adper PENTIXAPHARM to Eckert & Zieg\u00adler Strah\u00adlen- und Medi\u00adzin\u00adtech\u00adnik AG. In the course of the tran\u00adsac\u00adtion, Eckert & Zieg\u00adler acqui\u00adred a direct majo\u00adrity stake in PENTIXAPHARM, a joint venture between Scin\u00adto\u00admics GmbH and 1717 Life Science Ventures GmbH.<\/p>\n
With a solid history of buil\u00adding successful radio\u00adphar\u00admaceu\u00adti\u00adcal start\u00adups, the 1717 team has perso\u00adnal expe\u00adri\u00adence in all key func\u00adtions of an early-stage radio\u00adphar\u00admaceu\u00adti\u00adcal deve\u00adlo\u00adp\u00adment company. PENTIXAPHARM is deve\u00adlo\u00adping a radio\u00adphar\u00admaceu\u00adti\u00adcal combi\u00adna\u00adtion product against lymphoma and a number of rela\u00adted tumors. Toge\u00adther with an inter\u00adnal trans\u00adfer, Eckert & Zieg\u00adler says it will directly hold around 83% of the shares in the W\u00fcrz\u00adburg-based company after the closing. The manage\u00adment of PENTIXAPHARM, which holds the remai\u00adning 17% of PENTIXAPHARM shares, also recei\u00adved put opti\u00adons on the remai\u00adning shares as part of the share sale. More infor\u00adma\u00adtion can be found here.<\/p>\n
SMP had alre\u00adady advi\u00adsed on the estab\u00adlish\u00adment of the joint venture in 2019.<\/p>\n
1717 LSV empowers scien\u00adtists and inves\u00adtors to trans\u00adform early stage radio\u00adphar\u00admaceu\u00adti\u00adcal projects into attrac\u00adtive assets for licen\u00adsing part\u00adners in industry.<\/p>\n
About 1717 Life Science Ventures GmbH<\/strong> Advi\u00adsor 1717 Life Science Ventures GmbH: SMP<\/strong> About SMP<\/strong> Berlin \u2014 SMP provi\u00added legal advice to 1717 Life Science Ventures on the sale of its stake in drug deve\u00adlo\u00adper PENTIXAPHARM to Eckert & Zieg\u00adler Strah\u00ad\u00adlen- und Medi\u00adzin\u00adtech\u00adnik AG. In the course of the tran\u00adsac\u00adtion, Eckert & Zieg\u00adler acqui\u00adred a direct majo\u00adrity stake in PENTIXAPHARM, a joint venture between Scin\u00adto\u00admics GmbH and 1717 Life Science [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":37387,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366,1367,1368,1369,1373],"tags":[],"class_list":["post-43461","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","category-lawyers-tax-advisors-auditors-en","category-lawyers-tax-consultants-auditors","category-investors","category-venture-capital-en","news-category-venture-capital-news"],"yoast_head":"\n
\nBy intro\u00addu\u00adcing early stage inves\u00adtors to promi\u00adsing new projects, 1717 LSV seeks to enable novel radio\u00adphar\u00admaceu\u00adti\u00adcal thera\u00adpies to traverse the early stages of manu\u00adfac\u00adtu\u00adring and clini\u00adcal development.
\nWe laun\u00adched 1717 LSV in March 2018 to trans\u00adlate scien\u00adti\u00adfic results into pati\u00adents bene\u00adfits by filling the opera\u00adtio\u00adnal and finan\u00adcial gaps between the inven\u00adtion of radio\u00adphar\u00admaceu\u00adti\u00adcal subs\u00adtances and their first clini\u00adcal trials. We are focu\u00adsed, but not limi\u00adted, to onco\u00adlogy indi\u00adca\u00adti\u00adons to apply the full concept of Theranostics.<\/p>\n
\nDr. Martin Scha\u00adper, Partner<\/p>\n
\nSMP is a specia\u00adlist tax and commer\u00adcial law firm opera\u00adting in the core areas of corpo\u00adrate, funds, liti\u00adga\u00adtion, tax and tran\u00adsac\u00adtions. SMP\u2019s attor\u00adneys and tax advi\u00adsors repre\u00adsent a wide variety of clients. These include emer\u00adging tech\u00adno\u00adlogy compa\u00adnies and family-run medium-sized enter\u00adpri\u00adses as well as corpo\u00adra\u00adti\u00adons and private equity\/venture capi\u00adtal funds. Since its foun\u00adda\u00adtion in 2017, SMP has become one of the leading addres\u00adses for venture capi\u00adtal, private equity and fund struc\u00adtu\u00adring in Germany. The firm and its part\u00adners are natio\u00adnally and inter\u00adna\u00adtio\u00adnally ranked by JUVE, Best Lawy\u00aders, Legal 500, Focus, and Cham\u00adbers and Part\u00adners. Today, SMP employs more than 60 expe\u00adri\u00aden\u00adced lawy\u00aders, tax advi\u00adsors and tax specia\u00adlists in three offices in Berlin, Hamburg and Colo\u00adgne. For more infor\u00adma\u00adtion: www.smp.law and www.linkedin.com\/company\/smp.law.<\/p>\n","protected":false},"excerpt":{"rendered":"